We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock
GTHX

Delisted

GTHX was delisted on the 17th of September, 2024.

Back to rankings

116 hedge funds and large institutions have $123M invested in G1 Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 32 increasing their positions, 30 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more call options, than puts

Call options by funds: $550K | Put options by funds: $341K

50% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 24

12% more funds holding

Funds holding: 104 → 116 (+12)

7% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 30

57% less capital invested

Capital invested by funds: $287M → $123M (-$164M)

Holders
116
Holders Change
+12
Holders Change %
+11.54%
% of All Funds
1.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
36
Increased
32
Reduced
30
Closed
24
Calls
$550K
Puts
$341K
Net Calls
+$209K
Net Calls Change
-$537K

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$6.3M
2
Renaissance Technologies
Renaissance Technologies
New York
+$4.56M
3
Millennium Management
Millennium Management
New York
+$4.18M
4
Marshall Wace
Marshall Wace
United Kingdom
+$3.04M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$2.93M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$12.1M
2
PBA
Paradigm Biocapital Advisors
New York
-$11M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$4.32M
4
CSS
Cubist Systematic Strategies
Connecticut
-$3.11M
5
EI
EAM Investors
California
-$2.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
PP
126
PDT Partners
New York
– -$570K -45,605 Closed
AWM
127
AE Wealth Management
Kansas
– -$550K -44,005 Closed
ADIM
128
Alpha DNA Investment Management
Maryland
– -$530K -42,477 Closed
VF
129
Virtu Financial
New York
– -$436K -34,923 Closed
SFI
130
Susquehanna Fundamental Investments
Pennsylvania
– -$226K -18,100 Closed
LP
131
LMR Partners
United Kingdom
– -$177K -14,133 Closed
BPA
132
Beacon Pointe Advisors
California
– -$164K -13,200 Closed
LPL Financial
133
LPL Financial
California
– -$157K -12,590 Closed
GCP
134
GSA Capital Partners
United Kingdom
– -$138K -11,042 Closed
US Bancorp
135
US Bancorp
Minnesota
– -$34K -2,736 Closed
SA
136
SRH Advisors
Kansas
– -$22K -1,750 Closed
MIM
137
Macroview Investment Management
Maryland
– -$10K -819 Closed
DFCM
138
Dark Forest Capital Management
Puerto Rico
– -$6K -502 Closed
CG
139
Cutler Group
California
– -$3K -300 Closed
QC
140
Quent Capital
New York
– -$1K -86 Closed
2 3 4 5
6

GTHX Hedge Fund Activity: Q4 2022 in Review

116 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q4 2022, worth a combined $123M — down 57% from $287M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new GTHX positions and 24 closed out — a net gain of 12 holders — while 32 added to existing stakes and 30 trimmed.

The largest buyer was Woodline Partners, adding an estimated $6.3M. The largest seller was State Street, cutting an estimated $12.1M.

  • 116 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q4 2022, up from 104 in Q3 2022.
  • Funds reported $123M of G1 Therapeutics, Inc. Common Stock stock for Q4 2022, down 57% quarter-over-quarter.
  • 36 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q4 2022 and 24 closed out, a net change of +12 holders.
  • The largest G1 Therapeutics, Inc. Common Stock buyer in Q4 2022 was Woodline Partners, an estimated $6.3M added.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q4 2022 was State Street, an estimated $12.1M sold.

Based on aggregated 13F filings for Q4 2022.